论文部分内容阅读
目的:探讨经计算机辅助药物设计的抗癌多肽A38,或与顺铂联合应用对人胃癌细胞株SGC-7901的体外生长抑制作用及对肿瘤细胞早期凋亡的影响。方法:将人胃癌细胞株SGC-7901与不同浓度的A38、顺铂及A38+顺铂(DDP)分别进行体外培养,采用四甲基偶氮唑蓝法测定不同浓度的A38、顺铂及联合用药组在作用24,48,72 h后对SGC-7901细胞的生长抑制率;流式细胞仪分析细胞的凋亡率。结果:不同浓度A38、顺铂及联合用药后,SGC-7901细胞生长抑制率在不同浓度不同时段较对照组均显著增加(P均<0.01),联合用药组细胞生长抑制率较两单药组也明显增强(P均<0.01),呈现明显时效和量效关系。流式细胞仪检测凋亡结果显示:A38、顺铂及联合用药后,SGC-7901细胞的凋亡率在不同浓度不同时段较对照组均显著增加(P均<0.01),联合用药组细胞的凋亡率较两单药组也明显增加(P均<0.01)。结论:A38能抑制人胃癌细胞株SGC-7901细胞生长,诱导肿瘤细胞早期凋亡,小剂量顺铂与A38联用具有协同抑制作用,且效果比高浓度下的单用A38或单用顺铂的抑制作用明显。
Objective: To investigate the inhibitory effect of anti-cancer peptide A38 designed by computer-aided drug on human gastric cancer cell line SGC-7901 in vitro and its effect on the early apoptosis of tumor cells. Methods: Human gastric cancer cell line SGC-7901 and different concentrations of A38, cisplatin and A38 + cisplatin (DDP) were cultured in vitro, respectively, with different concentrations of A38, Cisplatin and combination therapy The inhibition rate of SGC-7901 cells after 24, 48 and 72 h of treatment was observed by flow cytometry. The apoptosis rate of SGC-7901 cells was analyzed by flow cytometry. Results: The growth inhibition rates of SGC-7901 cells were significantly increased at different concentrations of A38, cisplatin and combination therapy (P <0.01), and the cell growth inhibition rates of the combination group were significantly higher than those of the two drug groups Also significantly enhanced (P <0.01), showing significant aging and dose-effect relationship. The results of flow cytometry showed that the apoptotic rate of SGC-7901 cells was significantly increased at different time points after A38, cisplatin and combination treatment (all P <0.01) Apoptosis than two single drug group also increased significantly (P all <0.01). CONCLUSION: A38 can inhibit the growth of human gastric cancer cell line SGC-7901 and induce early apoptosis of tumor cells. A38 synergistic inhibitory effect of low dose cisplatin combined with A38 is better than that of A38 alone or cisplatin The inhibitory effect is obvious.